Two Seas Capital LP Makes New Investment in Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Two Seas Capital LP acquired a new stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 14,835,146 shares of the biotechnology company's stock, valued at approximately $7,992,000. Adaptimmune Therapeutics comprises 0.7% of Two Seas Capital LP's portfolio, making the stock its 20th largest holding. Two Seas Capital LP owned approximately 5.80% of Adaptimmune Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. Invesco Ltd. lifted its holdings in shares of Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after buying an additional 28,526 shares during the period. Virtu Financial LLC boosted its stake in Adaptimmune Therapeutics by 27.5% in the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 21,769 shares in the last quarter. Jane Street Group LLC grew its stake in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock valued at $166,000 after purchasing an additional 98,581 shares during the last quarter. LPL Financial LLC boosted its holdings in shares of Adaptimmune Therapeutics by 106.5% in the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 94,623 shares during the last quarter. Finally, Rock Springs Capital Management LP raised its stake in shares of Adaptimmune Therapeutics by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after buying an additional 58,000 shares during the last quarter. Institutional investors own 31.37% of the company's stock.

Adaptimmune Therapeutics Price Performance

Shares of Adaptimmune Therapeutics stock traded up $0.00 on Wednesday, hitting $0.27. The company had a trading volume of 498,709 shares, compared to its average volume of 1,753,618. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The company has a market cap of $68.35 million, a PE ratio of -1.21 and a beta of 2.84. The business has a 50-day simple moving average of $0.34 and a 200-day simple moving average of $0.55. Adaptimmune Therapeutics plc has a 52 week low of $0.20 and a 52 week high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The firm had revenue of $3.22 million during the quarter, compared to analysts' expectations of $16.56 million. Research analysts expect that Adaptimmune Therapeutics plc will post -0.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ADAP shares. HC Wainwright reduced their price target on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. StockNews.com assumed coverage on Adaptimmune Therapeutics in a research note on Wednesday. They set a "buy" rating on the stock. Jones Trading downgraded shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 11th. Scotiabank decreased their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research note on Friday, March 21st. Finally, Guggenheim decreased their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research report on Wednesday, March 26th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Adaptimmune Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $1.83.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.